Current status of allogeneic hematopoietic stem cell transplantation for treatment of peripheral T-cell lymphoma

VernacularTitle: 异基因造血干细胞移植治疗外周T细胞淋巴瘤现状
Author: Wenrong HUANG ¹ ; Daihong LIU
Author Information

1. Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China
Publication Type:Review
Keywords: Peripheral T-cell lymphoma; Allogeneic hematopoietic stem cell transplantation; Treatment
From: Journal of Leukemia & Lymphoma 2018;27(5):305-307
CountryChina
Language:Chinese
Abstract: Peripheral T-cell lymphoma (PTCL) is a kind of heterogeneous neoplasms mostly with strong invasiveness, a tendency of recurrence and drug resistance and poor prognosis. Five year disease-free-survival (DFS) rate of PTCL is less than 30% under the treatment setting of chemotherapy and autologous stem cell transplantation. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has a role of a graft-versus-lymphoma effect in the treatment of PTCL, meanwhile, long DFS rate of allo-HSCT for the treatment of relapsed and refractory PTCL reaches 35%-50%. Therefore, allo-HSCT is an effective treatment method for PTCL patients.